Pulmonx to Report First Quarter 2022 Financial Results on May 3, 2022
Pulmonx Corporation (Nasdaq: LUNG) will release its Q1 2022 financial results on May 3, 2022, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can participate by calling (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 2575271. The event will also be accessible via a live and archived webcast on the company's website.
- Company's Zephyr Valve has been used on over 25,000 patients across more than 25 countries.
- No significant financial metrics or guidance provided, leaving uncertainty for investors.
REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Tuesday, May 3, 2022. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 2575271. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves, please visit https://uspatients.pulmonx.com/. For more information on the company, please visit www.Pulmonx.com.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
When will Pulmonx release its Q1 2022 financial results?
How can I listen to Pulmonx's financial results conference call?
What time will the Pulmonx conference call take place?
Where can I find the webcast of the Pulmonx conference call?
